三诺生物公告，2025年上半年营业收入22.64亿元，同比增长6.12%。净利润1.81亿元，同比下降 8.52%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-070 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 第五届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经认真审核，监事会认为：公司《2025 年半年度报告》《2025 年半年度报告 摘要》的编制和审议程序符合相关法律、行政法规和规范性文件的规定，符合中 国证券监督管理委员会和深圳证券交易所以及公司内部管理制度的各项要求，报 告内容真实、准确、完整地反映了公司报告期内的实际经营情况，不存在虚假记 载、误导性陈述和重大遗漏，同意《关于〈公司 2025 年半年度报告全文〉及其 摘要的议案》。 具体内容详见公司同日在中国证监会指定的创业板信息披露网站（巨潮资讯 网 www.cninfo.com.cn）上披露的《2025 年半年度报告》《2025 年半年度报告摘 要》。 表决结果：3 票赞成，0 票反对，0 票弃权，审议通过。 三、备查文件 一、会议召开情况 三诺生物传感股份有限 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-069 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 第五届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"） 第五届董事会第二十次 会议于 2025 年 8 月 27 日（星期三）上午 10 时在公司会议室以现场结合通讯方 式召开。本次会议的通知已于 2025 年 8 月 17 日通过书面或电子邮件方式送达全 体董事。应出席本次会议的董事 7 人，实际出席本次会议的董事 7 人，分别为李 少波先生（兼任总经理）、李心一女士、车宏菁女士、李晖（LI HUI）先生、袁 洪先生、康熙雄先生、陈纪正女士。会议由董事长李少波先生召集并主持，公司 监事、高级管理人员列席了会议。会议的召集、召开符合《公司法》及《公司章 程》《公司董事会议事规则》的规定。 二、会议审议情况 本次会议采用现场和通讯表决方式进行表决，经与会董事认真审 ...

Core Viewpoint - Sanofi Biotech has established itself as a leader in the diabetes management sector, focusing on innovative solutions and expanding its product offerings to enhance patient care and health outcomes [1][2]. Group 1: Company Overview - Sanofi Biotech is recognized as the "first stock" in China's blood glucose industry and ranks as the fourth largest blood glucose meter company globally [1]. - The company serves over 25 million users worldwide, with products and services available in 187 countries and regions [1]. - In China, more than 50% of individuals who self-monitor their blood glucose levels use Sanofi's products [1]. Group 2: Strategic Direction - The company is extending its focus into diabetes medical services, emphasizing a digital management model that integrates biosensing, IoT, smart healthcare, and lifestyle guidance [2]. - Sanofi aims to shift diabetes management from a disease-centered approach to a health-centered approach, as outlined in the National Health Commission's plan for diabetes prevention and treatment from 2024 to 2030 [2]. Group 3: Product Development - Continuous Glucose Monitoring (CGM) systems are identified as a critical area for strategic development, providing comprehensive and reliable blood glucose information [2]. - Sanofi has completed the development of its second-generation CGM product, which has been launched domestically and received EU CE-MDR certification for sales in EU-recognized countries [3]. - The company is integrating artificial intelligence into chronic disease management, with its SinoGPT technology already operational [3]. Group 4: Future Investments - A global R&D center is set to be established, with an anticipated investment of 500 million yuan, focusing on the biosensing industry chain [3]. - Future R&D efforts will include artificial pancreas and insulin pump technologies to provide comprehensive solutions for chronic disease management [3].

三诺生物最新股价报21.09元，较前一交易日上涨0.43%。盘中最高触及21.17元，最低20.92元，成交金 额达2.81亿元。公司当前总市值118.16亿元，市盈率为40.96倍。 来源:金融界 资金流向方面，三诺生物当日主力资金净流出167.09万元，近五个交易日累计净流入2157.98万元。 风险提示：本文所提及个股仅作客观陈述，不构成任何投资建议。市场有风险，投资需谨慎。 作为医疗器械行业的重要企业，三诺生物专注于血糖监测产品的研发与生产。公司产品覆盖全球187个 国家和地区，服务超过2500万用户。在中国市场，超过50%的糖尿病自我监测人群使用三诺产品。 公司近期动态显示，位于湖南长沙的三诺全球研发中心即将落成。该中心预期投入5亿元，将重点开展 可穿戴设备、高端植入医疗设备等领域的研发工作。公司已完成第二代持续葡萄糖监测系统产品的研发 并实现国内上市，该产品同时获得欧盟CE-MDR认证。副董事长李心一表示，未来将在人工胰腺、胰岛 素泵等技术领域加大研发投入。 ...

Core Insights - The company aims to extend its services beyond just providing blood glucose meters to diabetes patients, focusing on comprehensive diabetes management and innovative product development [1][2] - The continuous glucose monitoring (CGM) system is identified as a core product for the company's next strategic development phase, with plans for smart, convenient, and comfortable product iterations [2][3] - The company has maintained an annual R&D investment exceeding 8% of revenue, with a global R&D center set to enhance capabilities in wearable and high-end implantable medical devices [3] Company Overview - Sanofi Biotech is recognized as the "first stock" in China's blood glucose industry and ranks as the fourth largest blood glucose meter company globally, serving over 25 million users across 187 countries [1] - More than 50% of the self-monitoring diabetes population in China uses the company's products, indicating a strong market presence [1] Product Development - The company has successfully launched its second-generation CGM product in China, which has received EU CE-MDR certification, allowing for sales in EU member states [2] - The introduction of artificial intelligence technology for chronic disease management is underway, with the development of SinoGPT facilitating a closed-loop system between diagnosis, hardware, and user data [2][3] Future Directions - The company plans to invest in research and development for technologies such as artificial pancreas and insulin pumps, aiming to provide comprehensive solutions for chronic disease management [3] - The focus will remain on innovation, transitioning from CGM to CXM, and from dynamic blood glucose monitoring to multi-parameter dynamic monitoring [3]

Group 1: Institutional Research and Shareholder Activity - The top twenty companies with the most institutional research in the last 30 days include Dongpeng Beverage, Zhongchong Co., Hikvision, Defu Technology, and Xinyi Technology[5] - In the last five days, the most researched companies include Nanwei Medical, Anjisi, Jinchengzi, Xinqianglian, and Baiya Co.[5] - Among the top twenty companies with institutional research in the last 30 days, 12 companies had 10 or more rating agencies, including Dongpeng Beverage, Zhongchong Co., and Hikvision[5] Group 2: Shareholder Buybacks - From August 11 to August 15, 2025, 51 companies announced buyback progress, with 10 having 10 or more rating agencies, and only 2 companies (Baolong Technology and Fuanna) had buyback amounts exceeding 1% of their market value[25] - From January 1 to August 15, 2025, 1,662 companies announced buyback progress, with 364 having 10 or more rating agencies, and 99 companies had buyback amounts exceeding 1% of their market value[27] Group 3: Shareholder Increase Activity - From August 11 to August 15, 2025, only 5 companies with significant shareholder increases had amounts below 1% of their market value[19] - From January 1 to August 15, 2025, 251 companies announced significant shareholder increases, with 67 having 10 or more rating agencies, and 19 companies had amounts exceeding 1% of their market value[21]

Core Insights - The company has launched several new products since 2025, including the Yuzhun SC801/SC801Air blood glucose meter and the Zhangyou M101/M101air blood uric acid and lipid meter, which have expanded its product application areas and target demographics [1] - The company has also upgraded existing products, such as the second generation of the San Nuo dynamic blood glucose meter and the EA-19 Pro uric acid and blood glucose meter, optimizing its product structure and industrial layout [1] - Future product launches will focus on multi-parameter monitoring and chronic disease management to meet user needs for family health [1] - In Q1 2025, the company reported revenue of 1.042 billion yuan, a year-on-year increase of 2.76%, while the net profit attributable to shareholders was 72 million yuan, a year-on-year decrease of 10.90% [1]

Group 1: Institutional Research on Popular Companies - The top twenty companies with the highest number of institutional research visits in the past 30 days include Dongpeng Beverage, Zhongchong Co., Hikvision, Defu Technology, and Xinyi Technology [10][11] - In the last five days, the most popular companies for institutional research include Nanwei Medical, Anjisi, Jinchengzi, New Strong Union, and Baiya Co. [10][11] - Among the top twenty companies in the past 30 days, twelve companies had ten or more rating agencies, including Dongpeng Beverage, Zhongchong Co., Ninebot, Baiya Co., Hikvision, Jereh, Xinyi Technology, Hongfa Technology, Nanwei Medical, Baijia Shenzhou, Huaming Equipment, and Shijia Photon [10][11] - Companies such as Xinyi Technology, Dongpeng Beverage, Zhongchong Co., and Ninebot are expected to see significant growth in net profit attributable to shareholders in 2024 compared to 2023 [10][11] Group 2: Shareholder Increase and Buyback Situations - From August 11 to August 15, 2025, five companies announced significant shareholder increases, but the average proposed increase amount was less than 1% of the market value on the announcement date [14] - From January 1 to August 15, 2025, a total of 251 companies announced shareholder increases, with 67 having ten or more rating agencies. Among these, 19 companies had an average proposed increase amount exceeding 1% of the latest market value, including Xinjie Energy, Tunnel Co., Sailun Tire, and Wanrun Co. [15] - During the same period, 1,662 companies announced buyback progress, with 364 having ten or more rating agencies. Among these, 99 companies had a proposed buyback amount exceeding 1% of the market value [19] Group 3: Buyback Progress - From August 11 to August 15, 2025, 51 companies announced buyback progress, with 10 having ten or more rating agencies. Only two companies, Baolong Technology and Fuanna, had a proposed buyback amount exceeding 1% of the market value [18] - From January 1 to August 15, 2025, 99 companies were in the board proposal stage for buybacks, including Liu Gong, Sanor Biotech, Shantui, Haixing Electric, Jiayi Co., and Gaoneng Environment [19] Group 4: Institutional Fund Flow - During the week of August 11 to August 15, 2025, sectors such as power equipment, electronics, real estate, non-bank financials, public utilities, computers, home appliances, building materials, light industry manufacturing, and banking received net inflows from institutional funds [24]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗器械板块主力资金净流出6.22亿元，游资资金净流入8454.45万元，散户资 金净流入5.38亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300049 | 福瑞股份 | 1.46 Z | 11.88% | -1.05 Z | -8.52% | -4138.97万 | -3.36% | | 300003 | 乐普医疗 | 1.21 Z | 7.97% | -5108.00万 | -3.37% | -6962.47万 | -4.59% | | 600645 | 中源协和 | 9348.49万 | 9.75% | -3949.64万 | -4.12% | -5398.85万 | -5.63% | | 688271 | 联影医疗 | ...